NAFLD VS MAFLD. The evidence-based debate has come. Time to change?

Annals of Hepatology, Journal Year: 2022, Volume and Issue: 27(6), P. 100765 - 100765

Published: Sept. 28, 2022

Non-alcoholic fatty liver disease (NAFLD) affects one-third of the world's adult population and is linked to metabolic syndrome. It can progress steatohepatitis, cirrhosis hepatocellular carcinoma. During last four decades, it has been subject exhaustive research in multiple aspects define its epidemiology, pathophysiological mechanisms therapy. In 2020, a group international experts proposed change name metabolic-associated (MAFLD) with main objective making an inclusive diagnosis prioritizing abnormalities. However, terminology included modification diagnostic criteria allowing non-exclusion other concomitant diseases such as alcohol disease, chronic hepatitis B or C. The proposal precipitated wave debates among based on theoretical opinions desirability rapid adoption new terminology. But also epidemiological clinical studies which, two years later, have provided evidence differences similarities entities, specially, those that could be considered for future refinements MAFLD. Likewise, this may contribute deciding time text, we discuss, general terms, important generated date cross-sectional longitudinal focusing characteristics outcomes, mainly all-cause specific mortality

Language: Английский

---

The Steatosis-associated fibrosis estimator (SAFE) score: validation in the general US population

Hepatology Communications, Journal Year: 2023, Volume and Issue: 7(4)

Published: April 1, 2023

Background: Noninvasive tests are important in the initial risk stratification of people at fibrosis. The recently developed steatosis-associated fibrosis estimator (SAFE) score may have such potential but awaits external validation. Methods: We analyzed 6973 participants aged 18–80 National Health and Nutrition Examination Survey 2017-2020 cycle with data on liver stiffness SAFE without prevalent heart failure. Fibrosis was defined as ≥8.0 kPa. Accuracy evaluated by AUC assessment test characteristics prespecified cutoffs for ruling out/ruling Results: categorized 14.7% population high risk, 30.4% intermediate 54.9% low actual prevalence these groups 28.0%, 10.9%, 4.0%, respectively, translating into a positive predictive value 0.28 high-risk cutoff negative 0.96 low-risk cutoff. (0.748) significantly higher than fibrosis-4 index (0.619) or NAFLD (0.718). However, performance strongly depended age categories: 90% 18–40 years were considered fibrosis, including 89/134 (66%) clinically significant cases. In oldest group (60–80 y), could only be safely ruled out among 17%, corresponding to referral rate up 83%. best found middle-aged (40–60 y). results consistent target populations metabolic dysfunction steatosis. Conclusions: has overall good diagnostic accuracy detecting highly dependent age. lacked sensitivity younger ability rule older populations.

Language: Английский

---

Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups

Nutrition Metabolism and Cardiovascular Diseases, Journal Year: 2024, Volume and Issue: 34(9), P. 2085 - 2094

Published: May 22, 2024

Language: Английский

---

Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study

Hepatology International, Journal Year: 2024, Volume and Issue: 18(4), P. 1168 - 1177

Published: May 28, 2024

Language: Английский

---

Global, Regional, and National Trends in Liver Disease-Related Mortality Across 112 Countries From 1990 to 2021, With Projections to 2050: Comprehensive Analysis of the WHO Mortality Database

Journal of Korean Medical Science, Journal Year: 2024, Volume and Issue: 39(46)

Published: Jan. 1, 2024

Liver disease causes over two million deaths annually worldwide, comprising approximately 4% of all global fatalities. We aimed to analyze liver disease-related mortality trends from 1990 2021 using the World Health Organization (WHO) Mortality Database and forecast rates up 2050.

Language: Английский

---

The correlation between hepatic fat fraction on dual-energy CT and epicardial adipose tissue in patients with non-alcoholic fatty liver disease

Journal of Radiation Research and Applied Sciences, Journal Year: 2025, Volume and Issue: 18(2), P. 101325 - 101325

Published: Feb. 10, 2025

Language: Английский

---

Metabolic dysfunction–associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease

Medicine, Journal Year: 2025, Volume and Issue: 104(6), P. e41455 - e41455

Published: Feb. 7, 2025

The term metabolic dysfunction–associated fatty liver disease (MAFLD) has been proposed based on a redefinition of the nonalcoholic (NAFLD) criteria. Our study aimed to address knowledge gap by comparing diagnostic accuracy MAFLD and NAFLD criteria in identifying significant fibrosis among patients with hepatic steatosis. A cross-sectional was conducted 2626 steatosis treated at Beijing Ditan Hospital between January 2009 December 2022. Patients viral hepatitis were excluded. Significant defined as Meta-analysis Histological Data Viral Hepatitis (METAVIR) score F ≥ 2. diagnosed 478 428 patients, respectively. Clinicopathological characteristics compared MAFLD+ NAFLD– group (patients who met for but not NAFLD) MAFLD– NAFLD+ MAFLD). total 743 histologically verified analyzed. comprised 163 (21.9%) 113 (15.2%) patients. older more likely be male had higher body mass index stiffness levels than those group. prevalence (43.6% vs 15.9%, P < .001). may better indicator Fibrosis can determined disorders, excessive alcohol consumption.

Language: Английский

---

Sleep Duration, Midpoint, Variability, Irregularity and Metabolic Dysfunction-Associated Steatotic Liver Disease

Behavioral Sleep Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14

Published: March 13, 2025

Objectives The relationship between actigraphy-derived sleep parameters, day-to-day deviations in and metabolic dysfunction-associated steatotic liver disease (MASLD), a new definition of nonalcoholic fatty (NAFLD), remains unclear. We aimed to explore the associations duration, midpoint, variability irregularity with MASLD risk.

Language: Английский

---

Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease

Hepatology Research, Journal Year: 2023, Volume and Issue: 53(7), P. 618 - 628

Published: March 11, 2023

The antidiabetic drugs sodium glucose cotransporter 2 inhibitors (SGLT2is) and thiazolidinediones have beneficial effects on the liver dysfunction of patients with nonalcoholic fatty disease type diabetes mellitus (T2DM). We aimed to determine efficacy these for treatment in metabolic dysfunction-associated (MAFLD) T2DM.We undertook a retrospective study 568 MAFLD T2DM. Of these, 210 were treating their T2DM SGLT2is (n = 95), 86 pioglitazone (PIO), 29 both. primary outcome was change Fibrosis-4 (FIB-4) index between baseline 96 weeks.At weeks, mean FIB-4 had significantly decreased (from 1.79 ± 1.10-1.56 0.75) SGLT2i group, but not PIO group. aspartate aminotransferase platelet ratio index, serum alanine (ALT), hemoglobin A1c, fasting blood sugar both groups (ALT: -17 3 IU/L; -14 IU/L). bodyweight group decreased, that increased (-3.2 kg +1.7 kg, respectively). When participants allocated two according ALT (>30 IU/L), groups. In taking pioglitazone, addition improved enzymes weeks.Treatment causes larger improvement than over weeks.

Language: Английский

---

Two years on, a perspective on MAFLD

eGastroenterology, Journal Year: 2023, Volume and Issue: 1(2), P. e100019 - e100019

Published: Sept. 1, 2023

To provide clarity for research studies and clinical care, a set of positive criteria adults children with metabolic (dysfunction) associated fatty liver disease (MAFLD) was recently published has subsequently been widely endorsed. The development subsequent validation the MAFLD created momentum change. During course ongoing discussion on redefinition, some concerns have surfaced that we thought needs clarification. In this review, perspective bringing to key aspects raised.

Language: Английский

---